louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05622734: VOCALE LBD+ for Caregivers of Persons With Lewy Body Dementia
Official title: VOCALE LBD+ Leveraging Social Technologies and Problem-Solving Skills to Enhance Mastery Among Caregivers of Persons With Lewy Body Dementia
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Caregiver Burden
Lewy Body Disease
Stress
Skill, Coping
Lead sponsor: University of Washington
Sponsor class: OTHER
Collaborators: name: Emory University
name: National Institute on Aging (NIA)
First posted: 2022-11-21
Enrollment: 39
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: SUPPORTIVE_CARE

Brief summary: The goal of this clinical trial is to evaluate the feasibility, acceptability, and initial efficacy of the VOCALE LBD+ intervention in caregivers of persons living with Lewy Body Dementia. The main question\[s\] it aims to answer are:

* What is the extent to which the VOCALE LBD+ intervention affects caregiving mastery scores at the end of the eight-week intervention
* What is the extent to which a change in caregiving mastery scores is retained four weeks after the end of the VOCALE LBD+ intervention

Participants will be asked to participate in a fully online asynchronous VOCALE LBD+ intervention that involves a moderated web-based discussion platform, peer-to-peer support, didactic training, and problem-solving skill enactment.


Eligibility criteria: Inclusion Criteria:

* Informal and/or lay caregiver of a patient with LBD
* Can read, write, and speak English
* Has access to a device that can be used for videoconferencing and/or phone calls
* 18 years or older

Exclusion Criteria:

* Not an informal and/or lay caregiver
* Cannot read and write in English
* No access to a device that can be used for videoconferencing and/or phone calls Younger than 18 years old

Primary outcomes:
measure: Effect Size of Change From Baseline Caregiving Mastery at 4 Weeks
timeFrame: Baseline; 4 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Seattle
country: United States
facility: University of Washington School of Nursing
state: Washington
Study officials:
affiliation: University of Washington
name: Oleg Zaslavsky, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03870334: Efficacy and Safety of Oral BT-11 in Moderate to Severe Crohn's Disease
Official title: A Randomized, Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate Efficacy and Safety of Oral BT-11 in Moderate to Severe Crohn's Disease
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE2
Conditions: Crohn's Disease
Lead sponsor: NImmune Biopharma
Sponsor class: INDUSTRY
First posted: 2019-03-12
Enrollment: 27
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: This is a phase 2 randomized, placebo-controlled, double-blind, parallel-group multicenter induction study. The purpose of this study is to evaluate the efficacy and safety of oral BT-11 induction compared to placebo in subjects with moderate to severe CD. Approximately 100 sites will participate from Europe and the USA. A total of 150 subjects with moderate to severe CD (CDAI Score 220-450 and a Simplified Endoscopic Index of Severity of Crohn's Disease (SES-CD) SCORED ≥ 6 (≥ 4 for isolated ileitis) will be randomized in a 1:1 ratio to receive BT-11 1,000 mg or placebo. Each of the treatment arms will comprise 75 subjects. The randomization will be stratified by prior exposure to biologic therapy for CD (yes/no) and corticosteroid use at baseline (yes/no). The study consists of a 28-day screening period, a 12-week induction phase, and a 2-week post-treatment safety follow-up period.
Primary purpose: TREATMENT

Brief summary: This is a phase 2 randomized, placebo-controlled, double-blind, parallel-group multicenter induction study.


Eligibility criteria: Key Inclusion Criteria:

1. Subjects aged 18 to 75 years with a diagnosis of CD for at least 3 months;
2. Moderately to severely active CD as defined by: a CDAI score of 220 450, and an SES-CD scored ≥ 6 ( ≥ 4 for isolated ileitis) (centrally read);

Key exclusion criteria:

1. Ulcerative colitis;
2. Known current bacterial or parasitic pathogenic enteric infection; live virus vaccination within 12 weeks of screening.

Primary outcomes:
measure: Clinical Remission Rate
timeFrame: 12 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Tampa
country: United States
facility: Study Center
state: Florida
Study officials:
References:
Clinical trial NCT03200834: Comparison of D2 vs D3 Lymph Node Dissection for Right Colon Cancer (RICON)
Official title: Comparison of D2 vs D3 Lymph Node Dissection for Right Colon Cancer (RICON)
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: NA
Conditions: Colon Cancer
Keywords: Right colon cancer
D3 dissection
complete mesocolic excision
Hemicolectomy
Lead sponsor: G.V. Bondar Republican Cancer Center
Sponsor class: OTHER
Collaborators: name: Donetsk National Medical University
name: I.M. Sechenov First Moscow State Medical University
First posted: 2017-06-27
Enrollment: 239
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Comparing different method of surgical technique D2 lymph node dissection vs D3 for right colon cancer.


Eligibility criteria: Inclusion Criteria:

1. Agreement of the patient to participate in trial
2. Colon cancer (only adenocarcinoma )
3. The tumor located between the cecum and the right 1/3 of transverse colon
4. Tumors T3,Т4а,b N0-2 (II-III stages)
5. Tolerance of chemotherapy
6. ECOG 0-2

Exclusion Criteria:

1. Patients with distant metastases
2. Tumors T1-2 (I stage)
3. Complications of tumor (perforation and full bowel obstruction)
4. Previous radiotherapy or chemotherapy
5. Synchronous or metachronous tumors
6. Women during Pregnancy or breast feeding period

Primary outcomes:
measure: 5-year survival
timeFrame: Up to 5 years post-operative
Secondary outcomes:
measure: morbidity
timeFrame: within the first 30 days after surgery
measure: mortality
timeFrame: within the first 30 days after surgery
measure: Disease free survival 5 years after initial surgery
timeFrame: Up to 5 years post-operative
Other outcomes:
Locations:
city: Donetsk
country: Ukraine
facility: G.V. Bondar Republican Cancer Center
Study officials:
affiliation: M.Gorky Donetsk National Medical University
name: Vladimir Balaban, PhD
role: STUDY_DIRECTOR
References:
Clinical trial NCT01722734: Preserving ACTs - Text Reminders to Increase Adherence to ACT Treatment
Official title: Preserving ACTs - Text Reminders to Increase Adherence to ACT Treatment
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Malaria
Keywords: Malaria
ACTs
Lead sponsor: Harvard School of Public Health (HSPH)
Sponsor class: OTHER
First posted: 2012-11-07
Enrollment: 1140
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: A randomized controlled trial was conducted to assess the effectiveness of text reminders sent to ACT users through an automated text messaging system short-message-system.

Study hypothesis: text message reminders increase adherence

Detailed description: A randomized controlled trial was conducted to assess the effectiveness of text reminders sent to ACT users through an automated text messaging system short-message-system. Patients were enrolled at clinics and pharmacies upon receipt of ACTs and enrolled in the automated system for 3 days.

Eligibility criteria: Inclusion Criteria:

-subjects acquiring ACTs in Tamale, Ghana

Exclusion Criteria:

* subjects acquiring ACTs for non household members
* subjects under the age of 18
* subjects without access to cell phones
* subjects living more than 30 minutes from pickup location

Primary outcomes:
measure: Self-reported Adherence to Artemisinin-combination Therapy (ACT) Treatment
timeFrame: 70 hours
Secondary outcomes:
Other outcomes:
Locations:
city: Tamale
country: Ghana
facility: Study site
state: Northern Region
Study officials:
affiliation: Harvard School of Public Health (HSPH)
name: Gunther Fink, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Raifman JR, Lanthorn HE, Rokicki S, Fink G. The impact of text message reminders on adherence to antimalarial treatment in northern Ghana: a randomized trial. PLoS One. 2014 Oct 28;9(10):e109032. doi: 10.1371/journal.pone.0109032. eCollection 2014.
Clinical trial NCT04203134: Burning Mouth Syndrome Mouth Guard Prospective Study
Official title: Protective Mouth Guards in Burning Mouth Syndrome (Prospective Study)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Burning Mouth Syndrome
Burning Mouth
Lead sponsor: University of Florida
Sponsor class: OTHER
First posted: 2019-12-18
Enrollment: 8
Sex: ALL
Minimum age (years): 18
Maximum age (years): 100
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study will seek to test the effectiveness of a nonpharmacologic therapy for burning mouth syndrome (BMS). This nonpharmacologic therapy approach will be the fabrication a protective acrylic mouthguard for the maxillary arch and palate.

Detailed description: The study involves a nonpharmacologic and non-invasive treatment method for BMS which will be administered randomly (flipping a coin) to half of the study subjects, (case group) in addition to normal condition treatment protocol for BMS.

Eligibility criteria: Inclusion Criteria:

• New patients diagnosed with BMS seen in the oral medicine clinic for the study period.

Exclusion criteria includes:

• Patients with inconclusive diagnosis or evidence of underlying condition that may be causing oral burning therefore excluding BMS as a diagnosis

Inclusion Criteria:

Primary outcomes:
measure: Effectiveness in pain control
timeFrame: Baseline through 6 month
Secondary outcomes:
Other outcomes:
Locations:
city: Gainesville
country: United States
facility: University of Florida College of Dentistry
state: Florida
Study officials:
affiliation: University of Florida
name: Austin Belknap
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04483934: Treatment of Patients With Non-healing Wounds and Trophic Ulcers Using Autologous Dermal Fibroblasts
Official title: Treatment of Patients With Non-healing Wounds and Trophic Ulcers Using Local LED Phototherapy and Autologous Dermal Fibroblasts
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: Trophic Ulcer
Non-healing Wound
Non-Healing Ulcer of Skin
Keywords: Trophic Ulcer
Non-healing Wound
Dermal fibroblasts
Lead sponsor: Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus
Sponsor class: OTHER_GOV
Collaborators: name: Minsk Scientific-Practical Center for Surgery, Transplantation and Hematology
First posted: 2020-07-23
Enrollment: 12
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Treatment of patients with non-healing wounds and trophic ulcers using local LED phototherapy with local transplantation of autologous dermal fibroblasts

Detailed description: During the implementation of the project, it was planned to develop a method for the treatment of trophic ulcers using injection of autologous dermal fibroblasts in the wound.

The positive outlook for the effectiveness of photodiode therapy with dermal fibroblasts is due to the following:

* the ability of fibroblasts to stimulate tissue regeneration
* positive results of preclinical studies of the method of treatment of long-term non-healing wounds in animals (rats).

Twelve patients were included in the study. Dermal fibroblasts were isolated from the skin patients, cultured and then transplanted back to the wound.

The therapeutic dose of cells was 50k per cm2 of the wound area. Follow up patients monitoring was performed at 1, 2 and more months after injection.

Eligibility criteria: Inclusion Criteria:

* Trophic Ulcers
* Chronic non-healing wounds

Exclusion Criteria:

* acute and chronic infectious diseases: HIV, viral hepatitis, tuberculosis
* mental disorders
* pregnancy

Primary outcomes:
measure: Number of patients with tropic ulcers cured
timeFrame: 1 month
measure: Number of patients with treatment-related adverse events
timeFrame: 4 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Minsk
country: Belarus
facility: Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus
Study officials:
affiliation: Head of the Lab of Institute of Biophysics and Cell Engineering
name: Igor Volotovski, Prof
role: STUDY_DIRECTOR
affiliation: Head of 2nd Department of Surgical Diseases of BSMU
name: Stanislav Tretyak, Prof
role: STUDY_DIRECTOR
affiliation: Ass prof of 2nd Department of Surgical Diseases of BSMU
name: Evgeny Baranov, Dr
role: PRINCIPAL_INVESTIGATOR
affiliation: Lead Researcher of Institute of Biophysics and Cell Engineering
name: Zinaida Kvacheva, Dr
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05590234: Dexmedetomidine Combined With Bupivacaine for Erector Spinae Plane Block
Official title: Dexmedetomidine Combined With Bupivacaine for Erector Spinae Plane Block Versus Bupivacaine Alone for Postoperative Pain Control of Posterior Lumbosacral Spine Fixation Surgeries
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: Posterior Lumbosacral Spine Fixation Surgeries
Lead sponsor: October 6 University
Sponsor class: OTHER
First posted: 2022-10-21
Enrollment: 90
Sex: ALL
Minimum age (years): 20
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: As the posterior lumbosacral spine fixation surgeries are common spine procedures done nowadays due to different causes and as this spine procedure is mostly accompanied with moderate to severe postoperative pain, so it is necessary to find an effective and efficient postoperative analgesia for patients with this surgery.


Eligibility criteria: Inclusion Criteria:

* elective posterior lumbosacral spine fixation and fusion surgery due to different causes that diagnosed clinically and radiologically including MRI and Plain X ray

Exclusion Criteria:

* hypersensitivity to the drugs used in the study \[local anesthetics, non-steroidal anti-inflammatory drugs, opioids and the drug under investigation (dexmedetomidine)\]
* patients with any contraindication to regional anesthesia as skin infections at the site of the block
* history of bleeding disorders or receiving anticoagulant medications

Primary outcomes:
measure: Postoperative visual analogue scale (VAS)
timeFrame: the first 24 hours postoperative
measure: Amount of post operative opioid consumption for the first 24 hours
timeFrame: the first 24 hours postoperative
Secondary outcomes:
measure: Postoperative visual analogue scale (VAS)
timeFrame: the second 24 hour postoperative
measure: Amount of post operative opioid consumption for the second 24 hours
timeFrame: the second 24 hour postoperative
Other outcomes:
Locations:
city: Giza
country: Egypt
facility: October 6 university hospital
Study officials:
affiliation: October 6 University
name: Abdelmaksod Mohammed M Mousa, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06532734: Barrett's Esophagitis in Anorexia Nervosa Binge/Purge Subtype
Official title: Presence of Barrett's Esophagitis in a Cohort of People With Eating Disorders Who Engage in Purging Behaviors: A Pilot Study
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Barrett Esophagus
Anorexia Nervosa, Binge Eating/Purging Type
Rumination
Vomiting
Eating Disorders
Esophageal Adenocarcinoma
Lead sponsor: Denver Health and Hospital Authority
Sponsor class: OTHER
Collaborators: name: Lucid Diagnostics, Inc.
First posted: 2024-08-01
Enrollment: 25
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: ACUTE patients with a confirmed dx of AN-BP, with a purging history of \>5 year, with a frequency of purging of at least once a day.

Brief summary: To better define the presence of Barrett's esophagus (BE) via non-endoscopic testing in an eating disorder cohort with purging (vomiting/rumination) behaviors

Detailed description: A prospective cohort study to assess the presence of BE in those with purging behaviors from their eating disorders has not been completed. There are multiple case reports describing a younger population not meeting typical screening guidelines whom developed this condition. To better define the presence of Barrett's esophagus (BE) via non-endoscopic testing in an eating disorder cohort with purging (vomiting/rumination) behaviors. Individuals with severe forms of eating disorders with purging and ruminating behaviors not meeting the current screening guidelines for BE will still test positive for BE.

Eligibility criteria: Inclusion Criteria:

* Patients diagnosed with an eating disorder diagnosis that includes purging history
* Ages 18-65
* Purging history =\>5 years
* Purging or rumination at a minimum of once daily upon admission.
* Admission to the ACUTE Center for Eating Disorders and Severe Malnutrition

Exclusion Criteria:

* Any eating disorder diagnosis that does not include purging behaviors
* Ages under 18 and over 65
* Patients who otherwise meet the current ACG screening guidelines (chronic GERD and 3 or more risk factors for Barrett's mentioned in the Background)
* Received mandated care at time of enrollment
* Inability to consent to participate in the research

Primary outcomes:
measure: Number of patients positive for BE
timeFrame: 12 months
Secondary outcomes:
Other outcomes:
Locations:
city: Denver
country: United States
facility: ACUTE Center for Eating Disorders and Severe Malnutrition
state: Colorado
city: Denver
country: United States
facility: Denver Health and Hospital Authority
state: Colorado
city: Denver
country: United States
facility: Denver Health and Hospital Authority
state: Colorado
Study officials:
affiliation: Denver Health and Hospital Authority
name: Dennis J Gibson, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06821334: A Single Dose Study of MK-6194 in Healthy Chinese Participants (MK-6194-014)
Official title: A Randomized, Double-Blind, Placebo-Controlled Single Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics of MK-6194 in Healthy Chinese Participants
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Healthy
Lead sponsor: Merck Sharp & Dohme LLC
Sponsor class: INDUSTRY
First posted: 2025-02-12
Enrollment: 37
Sex: ALL
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: SEQUENTIAL
Primary purpose: BASIC_SCIENCE

Brief summary: The goal of this study is to learn how safe MK-6194 is in healthy Chinese adults and how well people tolerate it.


Eligibility criteria: Inclusion Criteria:

The key inclusion criteria include but are not limited to the following:

* Is in good health
* Has body mass index (BMI) within 18.0 to 28.0 kg/m\^2 (inclusive) and weight ≥50 kg

Exclusion Criteria:

The key exclusion criteria include but are not limited to the following:

* History of clinically significant endocrine, gastrointestinal (GI), cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological (including stroke and chronic seizures) abnormalities or diseases
* Has a history of opportunistic infection, Human immunodeficiency virus (HIV), hepatitis B, hepatitis C, tuberculosis

Primary outcomes:
measure: Number of Participants Who Experience an Adverse Event (AE)
timeFrame: Up to 42 days post dose
measure: Number of Participants Who Discontinue Study Due to an AE
timeFrame: Up to 42 days post dose
Secondary outcomes:
measure: Area Under the Concentration-Time Curve from Time 0 to Last Measurable Concentration (AUC0-Last) of MK-6194
timeFrame: Up to 42 days post dose
measure: Area Under the Concentration-Time Curve from Time 0 to Infinity (AUC0-Inf) of MK-6194
timeFrame: Up to 42 days post dose
measure: Maximum Serum Concentration (Cmax) of MK-6194
timeFrame: Up to 42 days post dose
measure: Time to Maximum Serum Concentration (Tmax) of MK-6194
timeFrame: Up to 42 days post dose
measure: Apparent Terminal Half-life (t1/2) of MK-6194
timeFrame: Up to 42 days post dose
measure: Apparent Clearance (CL/F) of MK-6194
timeFrame: Up to 42 days post dose
measure: Apparent Volume of Distribution during terminal phase (Vz/F) of MK-6194
timeFrame: Up to 42 days post dose
measure: Incidence of Antidrug Antibodies (ADA) to MK-6194
timeFrame: Up to 42 days post dose
Other outcomes:
Locations:
city: Beijing
country: China
facility: Peking University Third Hospital (Site 0001)
state: Beijing
Study officials:
affiliation: Merck Sharp & Dohme LLC
name: Medical Director
role: STUDY_DIRECTOR
References:
Clinical trial NCT01583634: Accuracy of Oximeters With Hypoxia and Methemoglobin or Carboxyhemoglobin
Official title: Accuracy of Oximeters With Hypoxia and Methemoglobin or Carboxyhemoglobin
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Healthy Volunteers
Lead sponsor: Mespere Lifesciences Inc.
Sponsor class: INDUSTRY
First posted: 2012-04-24
Enrollment: 9
Sex: ALL
Minimum age (years): 21
Maximum age (years): 49
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Healthy volunteers between the ages of 21 and 49 years of either gender, and a range of skin tones

Brief summary: Accuracy of the oximeter.

Detailed description: The conventional pulse oximeter has been a standard in clinical care for non-invasive hemodynamic monitoring, which only measures the arterial blood oxygenation. There are many clinical situations where tissue hypoxia may exist despite normal values obtained by conventional pulse oximeter. This can be cause by inadequate monitoring of oxygen demand (i.e. venous oxygen saturation) of the tissues.

The existing method for venous blood oxygenation monitored is either through an invasive fiber optic catheter, or intermittently by blood sampling and CO-oximetry. However, catheterization can be costly and can include inherent risks. Therefore, due to the inherent risks of catheterization, venous oximetry is limited only to those critically ill patients. The clinical application of venous oximetry is numerous, including severe sepsis and septic shock, severe trauma and hemorrhagic shock, and heart failure and cardiac arrest.

More complete information on patient hemodynamics can be provided by non-invasively monitoring of venous blood oxygenation.

Eligibility criteria: Inclusion Criteria:

* Healthy volunteers between the ages of 21 and 49 years of either gender

Exclusion Criteria:

* smokers
* pregnancy
* any chronic medical condition including heart disease, hypertension, pulmonary disease, liver or kidney disease
* obesity
* evidence of abnormal neck vein anatomy

Primary outcomes:
measure: Venous Oxygen Saturation Accuracy Verification against Co-Oximeter
timeFrame: approximately 1 hour
Secondary outcomes:
Other outcomes:
Locations:
city: San Francisco
country: United States
facility: University of California, San Francisco, Induced Hypoxia Lab
state: California
Study officials:
affiliation: University of California, San Francisco
name: Philip E Bickler, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References: